疾病
胰腺癌Pancreatic cancer
胰腺癌 · ICD-10：C25 — Malignant neoplasm of pancreas
关键数据
仅为已发布的数值。每个图块都会打开带有其来源、年份与口径的章节。
疾病详情
- 规范中文名
- 胰腺癌
- 英文名
- Malignant neoplasm of pancreas
以中文写出的数值按来源原样引用。
又称
- 胰腺恶性肿瘤
- 胰癌
- Pancreatic cancer
治疗费用区间
以下每个区间都按一种计费口径发布：医保报销前。 来源未发布报销后数值，因此这里不展示。
| 治疗路径 | 费用区间 | 价格依据 | 数据年份 |
|---|---|---|---|
| 手术 | 90000 – 90000 CNY | 病种打包全包价 | 2020 |
| 手术 | 85000 – 85000 CNY | 病种打包全包价 | 2020 |
上方的条形共用同一刻度：每条从该行已发布的下限值起，到其上限值止。本页最高的上限值为 90000 CNY。每行保留自己的数据年份与口径。
该疾病的 2 个费用区间，来源见各行页面。
以中文写出的数值按来源原样引用。
五年生存
5 年生存率 8.5% 95% 置信区间 8.2–8.7
- 人群
- 总体（全分期合并）· 年龄标准化相对生存率
- 时期
- 2019–2021
- 发布机构
- 国家癌症中心
- 数值性质
- 估计值（混合法）
- 登记范围
- 281 个肿瘤登记处
- 分期数据可用性
- 未发布
以中文写出的数值按来源原样引用。
如何解读该数据。 它按全分期合并发布，因此是全国登记数据中所有人的平均值，而不是对某个人的预后。对多数癌症而言，确诊时的分期是生存差异背后最强的单一因素：通常，癌症发现得越早，生存率越高；发现得越晚，越低。不同癌症之间的比较也受到各自通常确诊早晚的影响，因此一个较低的数值本身并不意味着诊疗更差。
该数值是相对生存率：它把被诊断患此癌的人与一般人群中同年龄、同性别的人相比较，且为年龄标准化，因此它不是五年后仍存活患者所占的比例。它以估计值（混合分析）发布，因为登记报告存在滞后，故国家癌症中心对最近一段时期作了模型估计。作为参照，同一来源发布 2019–2021 年全部癌症合计的五年相对生存率为 43.7%。
在该疾病上有已发布记录的医院
依据官方公开数据来源筛选
这些医院依据官方公开数据来源筛选——复旦大学医院专科声誉排行榜、国家临床重点专科名单与国家临床医学研究中心——因此卡片上的每一行都可与其已发布的来源核对。这不是付费或推广位。
这些医院是如何筛选的
入选。当某疾病所归属的专科满足以下至少一项时，医院即被列入该疾病：在复旦大学医院专科声誉排行榜中有一个名次或提名；有一条 A、B 或 C 级的国家临床重点专科记录；或该专科有一个国家临床医学研究中心或国家重点实验室。JCI 认证仅作徽标展示；它绝不决定入选，也绝不决定排序。
排序。第 1 步：该专科在复旦榜中的第 1 至第 10 名。第 2 步：又一个复旦名次，或一个提名。第 3 步：一条 A 级国家临床重点专科。第 4 步：一条 B 级国家临床重点专科。第 5 步：该专科的一个国家临床医学研究中心或国家重点实验室，研究中心优先于实验室。第 6 步：一条 C 级国家临床重点专科——这是我们发布的一条没有独立官方来源的记录，因此排在其余之后。
平局。在同一步骤内：复旦名次更好的在前，其次重点专科等级更高者（A 先于 B，B 先于 C），再次省份，再次城市，最后医院名称——与医院目录所用的省—市—名称顺序相同。最多列出八家医院。
当名单较短时。五家及以上：列出前八家。三家或四家：全部列出，并有一个可展开的折叠区，把其余记录补至最多八条，每条都带其证据等级。一两家：同上，且该折叠区默认展开，并有一行说明有多少家医院有可靠的公开记录。没有：页面说明未找到可靠的公开记录，并链接到专科目录。绝不为了凑数而编造名次、机构或数量。
复旦排行榜是中国临床医生最广泛认可的医院专科声誉排行榜，由复旦大学医院管理研究所每年发布。
-
中国医学科学院肿瘤医院Cancer Hospital of Chinese Academy of Medical Sciences
复旦专科声誉排行榜 2023
- Medical Oncology #1 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Medical Oncology（B 级） https://www.cicams.ac.cn/news/401.html
研究平台
- 国家恶性肿瘤临床医学研究中心 https://www.most.gov.cn/tztg/201306/t20130608_106459.html
同时上榜：在复旦榜中为 Thoracic Surgery #1, Urology 获提名。
-
中国医学科学院北京协和医院Peking Union Medical College Hospital
复旦专科声誉排行榜 2023
- General Surgery #1 https://www.fdygs.com/news2023-1.aspx
- Medical Oncology 获提名 https://www.fdygs.com/news2023-1.aspx
同时上榜：在复旦榜中为 Urology #8, Gynecology #1, Otorhinolaryngology #4。
-
复旦大学附属中山医院Zhongshan Hospital
复旦专科声誉排行榜 2023
- General Surgery #2 https://www.fdygs.com/news2023-1.aspx
- Medical Oncology 获提名 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- General Surgery（B 级） https://www.zs-hospital.sh.cn/zhuanye/content/5140.html
同时上榜：在复旦榜中为 Thoracic Surgery #6, Gastroenterology #9, Respiratory Medicine #6。
-
中山大学肿瘤防治中心Sun Yat-sen University Cancer Center
复旦专科声誉排行榜 2023
- Medical Oncology #2 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- General Surgery（B 级） https://www.sysucc.org.cn/node/8565
- Medical Oncology（B 级） https://www.sysucc.org.cn/node/8565
同时上榜：在复旦榜中为 Thoracic Surgery #9。
-
四川大学华西医院West China Hospital, Sichuan University
复旦专科声誉排行榜 2023
- General Surgery #3 https://www.fdygs.com/news2023-1.aspx
- Medical Oncology #8 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- General Surgery（A 级） https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
- Medical Oncology（A 级） https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
同时上榜：在复旦榜中为 Thoracic Surgery #4, Urology #2 （并列）, Otorhinolaryngology #8。
-
复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center
复旦专科声誉排行榜 2023
- Medical Oncology #3 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Medical Oncology（B 级） https://www.shca.org.cn/home/news/content/id/297/pid/25651
- Hepatobiliary Surgery（B 级） https://www.shca.org.cn/home/news/content/id/297/pid/25651
同时上榜：在复旦榜中为 Thoracic Surgery #10, 核医学 获提名。
-
上海交通大学医学院附属瑞金医院Ruijin Hospital
复旦专科声誉排行榜 2023
- General Surgery #4 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- General Surgery（B 级） https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
- Medical Oncology（B 级） https://www.rjh.com.cn/2018rjportal/rjzlk/ksjs/index.shtml
同时上榜：在复旦榜中为 Thoracic Surgery #7 （并列）, Respiratory Medicine #5, 传染感染 #6。
-
北京大学肿瘤医院Peking University Cancer Hospital
复旦专科声誉排行榜 2023
- Medical Oncology #4 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Medical Oncology（B 级） https://www.bjcancer.org/Html/Hospitals/Main/Description.html
同时上榜：在复旦榜中为 核医学 获提名。
临床试验（在研治疗）
除标准治疗外，针对 Pancreatic cancer 的临床研究目前可能在中国开放招募受试者。在研治疗尚未获监管机构批准为标准疗法——它们是临床研究，而非常规治疗。每条记录都注明主要研究者与开展研究的医院。如有兴趣，请联系医院了解是否符合条件，并自行决定是否申请。
-
研究 Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine As Postoperative Adjuvant Therapy in Patients with EGFR-positive Pancreatic Cancer: a Prospective, Single-arm Study
- 医院
- Zhejiang Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT06722911
-
研究 Nab-Paclitaxel/Gemcitabine Followed by mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Previously Untreated Advanced Pancreatic Cancer: A Randomized, Controlled, Multicenter Phase III Trial
- 主要研究者
- Ying Jieer · Director of Department
- 医院
- Zhejiang Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT07235930
-
研究 Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial
- 主要研究者
- Jinbo Yue · Jinbo Yue
- 医院
- Shandong Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT06050317
-
研究 Efficacy and Safety of Nano-Megestrol Acetate in the Treatment of Anorexia-Cachexia Syndrome in Patients With Advanced Pancreatic Cancer: A Randomized, Controlled, Prospective Study
- 主要研究者
- Jinbo Yue · Director of Radiation Oncology Department
- 医院
- Shandong Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT07408505
-
研究 Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) -A Single-Arm Phase Ib/II Trial
- 主要研究者
- Jinbo Yue · Director of Department Radiation Oncology
- 医院
- Shandong Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT06844422
另有 39 项已登记研究
-
研究 A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
- 医院
- Peking Union Medical College Hospital
- 状态
- 招募中
- 登记库
- NCT07678593
-
研究 A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
- 医院
- Tianjin Medical University Cancer Institute & Hospital
- 状态
- 招募中
- 登记库
- NCT06760364
-
研究 A Prospective Single-center Observational Study: ctDNA-guided Maintenance Therapy for Postoperative Pancreatic Cancer
- 主要研究者
- Du Juan · Chief Physician
- 医院
- Nanjing Drum Tower Hospital
- 状态
- 招募中
- 登记库
- NCT07054879
-
研究 Adjuvant Chemoradiotherapy Versus Chemotherapy for Post-operative Pancreatic Cancer
- 主要研究者
- Zhang Huo Jun
- 状态
- 招募中
- 登记库
- NCT06427447
-
研究 Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer
- 主要研究者
- Guo ShiWei
- 状态
- 招募中
- 登记库
- NCT04743479
-
研究 A Multicenter, Open-label, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Combination With Chemotherapy as First-line Treatment in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- 医院
- Peking Union Medical College Hospital
- 状态
- 招募中
- 登记库
- NCT05859750
-
研究 A Prospective Cohort Study on the Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer: A Comprehensive Analysis Based on Multidimensional Dynamic Psychological Assessment (MIND-PANC)
- 医院
- Xiangya Hospital of Central South University
- 状态
- 招募中
- 登记库
- NCT07529626
-
研究 The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
- 主要研究者
- Hu Jiajia · Deputy director
- 医院
- Ruijin Hospital
- 状态
- 招募中
- 登记库
- NCT06601010
-
研究 An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer
- 医院
- Peking University Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT05911217
-
研究 A Prospective, Single-Center, Phase II Clinical Study of Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen (Liposomal Irinotecan, Oxaliplatin, and S-1) Hepatic Arterial Infusion Chemotherapy (HAIC) and Intra-Arterial Programmed Death-1 (PD-1) Inhibitors for Liver Metastases From Pancreatic Cancer
- 主要研究者
- Zhongmin Wang · Principal Investigator
- 医院
- Ruijin Hospital
- 状态
- 招募中
- 登记库
- NCT07504471
-
研究 a Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial of HRS-4642 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as First-Line Therapy in Patients With Advanced or Metastatic Pancreatic Carcinoma Harboring KRAS G12D Gene Mutation
- 医院
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
- 状态
- 招募中
- 登记库
- NCT07232875
-
研究 Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
- 医院
- Ningbo Medical Center Lihuili Hospital
- 状态
- 招募中
- 登记库
- NCT07542002
-
研究 Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- 医院
- Henan Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT06375473
-
研究 A Multicenter Study Assessing the Efficacy and Safety of Icaritin in Combination With AG Chemotherapy Versus AG Chemotherapy Alone in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
- 医院
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- 状态
- 招募中
- 登记库
- NCT06825546
-
研究 An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer
- 主要研究者
- Liu Yang · MD
- 医院
- Zhejiang Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT07312422
-
研究 A Phase II Trial to Evaluate the Efficacy of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Pancreatic Tumors
- 医院
- Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
- 状态
- 招募中
- 登记库
- NCT07006077
-
研究 A Phase 1/2, Open-label, Biomarker-guided, Dose-escalation and Expansion Study of Dual-targeting CAR-NK Cells Directed Against Mesothelin (MSLN) and MUC1, With an Exploratory CLDN18.2/MUC1 Dual-target Cohort, in Patients With Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- 医院
- Peking University Shenzhen Hospital
- 状态
- 招募中
- 登记库
- NCT07627711
-
研究 A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer
- 医院
- Anhui Provincial Hospital
- 状态
- 招募中
- 登记库
- NCT06361888
-
研究 Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
- 主要研究者
- Jiang Long · Chief physician of hepatobiliary and pancreatic surgery
- 医院
- Shanghai General Hospital
- 状态
- 招募中
- 登记库
- NCT06531278
-
研究 A Proof of Concept Study of Pancreatic Cancer Early Detection by cfDNA Assay
- 主要研究者
- Xian-Jun Yu · Principal Investigator
- 医院
- Fudan University Shanghai Cancer Center
- 状态
- 招募中
- 登记库
- NCT06166147
-
研究 Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
- 主要研究者
- Jiang Long · Chief physician of hepatobiliary and pancreatic surgery
- 医院
- Shanghai General Hospital
- 状态
- 招募中
- 登记库
- NCT06307080
-
研究 Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.
- 主要研究者
- Li Tian, MD · Li Tian, MD [fu3tianli]
- 医院
- Xiangya Hospital of Central South University
- 状态
- 招募中
- 登记库
- NCT06655233
-
研究 A Single-arm, Exploratory Clinical Study of Trilaciclib Combined With mFOLFIRINOX Regimen in the Treatment of Patients With Advanced Pancreatic Cancer
- 医院
- Nanjing Drum Tower Hospital
- 状态
- 招募中
- 登记库
- NCT06151262
-
研究 Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- 主要研究者
- Guo ShiWei
- 状态
- 招募中
- 登记库
- NCT04146298
-
研究 A Randomized, Double-blind, Parallel-controlled, Multicenter Phase III Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules to Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- 医院
- First Affiliated Hospital of Guangzhou Medical University
- 状态
- 招募中
- 登记库
- NCT07165951
-
研究 A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
- 医院
- Zhongshan Hospital
- 状态
- 招募中
- 登记库
- NCT07561814
-
研究 An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
- 医院
- Zhongshan Hospital
- 状态
- 招募中
- 登记库
- NCT06938282
-
研究 An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- 主要研究者
- BAIYONG SHEN · Professor
- 医院
- Ruijin Hospital
- 状态
- 招募中
- 登记库
- NCT06587061
-
研究 Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pabolizumab in Patients With Advanced Pancreatic Cancer
- 医院
- Ruijin Hospital
- 状态
- 招募中
- 登记库
- NCT05916261
-
研究 Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial
- 主要研究者
- Dai, Guanghai · Professor
- 医院
- Chinese PLA General Hospital
- 状态
- 招募中
- 登记库
- NCT05218889
-
研究 A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- 主要研究者
- YiHui Guan · Professor
- 医院
- Huashan Hospital
- 状态
- 招募中
- 登记库
- NCT07707531
-
研究 A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.
- 主要研究者
- Dan Sha · Chief Physician
- 医院
- Shandong Provincial Hospital
- 状态
- 尚未招募
- 登记库
- NCT07333287
-
研究 A Multicenter, Single-arm, Prospective Study of SBRT Combined With Zimberelimab (GLS-010) in Patients With Locally Advanced Pancreatic Cancer (SPARK-1 Study)
- 医院
- Peking University Third Hospital
- 状态
- 尚未招募
- 登记库
- NCT06009029
-
研究 Human Chimeric Antigen Receptor Macrophages Targeting C-MET for C-MET-positive Advanced Stage of Pancreatic Cancer Patients: A Single-arm, Single-center, IIT Study
- 医院
- Peking Union Medical College Hospital
- 状态
- 尚未招募
- 登记库
- NCT07553793
-
研究 Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients
- 医院
- Peking Union Medical College Hospital
- 状态
- 尚未招募
- 登记库
- NCT07114666
-
研究 Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: An Open-Label, Single-Arm, Phase II Study
- 主要研究者
- Fan Wang · Associate Chief Physician
- 医院
- Shanghai General Hospital
- 状态
- 尚未招募
- 登记库
- NCT07733050
-
研究 A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
- 医院
- Xiangya Hospital of Central South University
- 状态
- 尚未招募
- 登记库
- NCT07231094
-
研究 Immune Repertoire Decoding Enables Dynamic Risk Stratification During Chronic Pancreatitis-to-Pancreatic Cancer Transition
- 主要研究者
- Zhuan Liao
- 状态
- 尚未招募
- 登记库
- NCT07762950
-
研究 The Efficacy and Safety of Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: A Prospective, Single Arm, Phase II Clinical Study
- 医院
- Zhongshan Hospital
- 状态
- 尚未招募
- 登记库
- NCT06166589
本页仅分享公开登记的研究信息，不推荐也不鼓励参加任何研究。参加完全自愿，且未经批准治疗的风险尚不明确；请直接联系医院了解入组条件与知情同意细节。
拥有国家临床重点专科记录的医院
显示医院记录 66 家拥有重点专科记录的医院
每一行都是在某疾病所归属专科中拥有国家临床重点专科记录的医院。这是对已发布名单的记录，既不构成推荐，也不是排名。
66 家拥有匹配的国家临床重点专科记录的医院。
以中文写出的数值按来源原样引用。
患者报告的情况
仅为汇总数据：一项全国性结果，附其来源与所指年份。这不是患者证言，也不是关于某一个人的陈述。
据 National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号)（2023）报道：National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100。
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
来源：National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — A 级
关于该疾病的问题
我们不能提供医疗建议，但可以回答关于本页以及在中国安排就医的问题。
ICD 编码
显示编码表 1 个 ICD 编码
| 版本 | 编码 | 该版本中的名称 |
|---|---|---|
| ICD-10-WHO | C25 | Malignant neoplasm of pancreas |
各行为该疾病的 WHO ICD-10 条目，按原样引用。
来源与证据
- 来源 URL
- https://qzybj.quanzhou.gov.cn/qt/gzcx/bzsfcx/202006/P020221216571645625406.pdf
- 来源协议
- https
- 来源类型
- 省级卫生健康委员会
- 证据等级
- A ——由卫生健康委员会、国家级研究机构或大学所述
- 获取日期
- 2026-09-30